Pre-made Demcizumab benchmark antibody ( Whole mAb, anti-DLL4 therapeutic antibody, Anti-AOS6/delta4/hdelta2 Antibody) for drug discovery and mechanism of action (MOA) research
Cat No.: GMP-Bios-ab-137
Pre-Made Demcizumab biosimilar, Whole mAb, Anti-DLL4 Antibody: Anti-AOS6/delta4/hdelta2 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Demcizumab /dɛmˈsɪzʊmæb/ is a humanized monoclonal antibody which is used to treat patients with pancreatic cancer or non-small cell lung cancer. Demcizumab has completed phase 1 trials and is currently undergoing phase 2 trials. Demcizumab was developed by OncoMed Pharmaceuticals in collaboration with Celgene.
Order information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Catalog No. | Package | List Price(In USD) | Discount off | Discount Price |
---|---|---|---|---|
GMP-Bios-ab-137-1mg | 1mg | 3090 | Inquiry | Inquiry |
Size: 1mg | 10mg | 100mg
Description
Products Name (INN Index) | Pre-Made Demcizumab biosimilar, Whole mAb, Anti-DLL4 Antibody: Anti-AOS6/delta4/hdelta2 therapeutic antibody |
INN Name | Demcizumab |
Target | DLL4 |
Format | Whole mAb |
Derivation | Humanized |
Species Reactivity | Human |
CH1 Isotype | IgG2 |
VD LC | Kappa |
Highest_Clin_Trial (Jan '20) | Phase-I |
Est. Status | Discontinued |
100% SI Structure | None |
99% SI Structure | None |
95-98% SI Structure | None |
Year Proposed | 2012 |
Year Recommended | 2013 |
Companies | Celgene Corporation;OncoMed Pharmaceuticals |
Conditions Approved | na |
Conditions Active | na |
Conditions Discontinued | Colorectal cancer;Fallopian tube cancer;Non-small cell lung cancer;Ovarian cancer;Pancreatic cancer;Peritoneal cancer;Solid tumours |
Development Tech | na |
- GENEMEDI
- Email: [email protected] [email protected]
- Telephone: +86-21-50478399 Fax: 86-21-50478399
- Privacy Policy
- TECHNICAL SUPPORT
- Product FAQs
- Technical manuals
- Publications
- Email: [email protected]
<